ClinicalTrials.gg
CompletedNCT02536404Updated Nov 26, 2021Results posted

Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis

A Phase 2 interventional study of Etrasimod and Placebo in Ulcerative Colitis, sponsored by Arena Pharmaceuticals. Completed at 127 sites in 21 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-11-26.

Sponsored by Arena Pharmaceuticals (part of Pfizer) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing etrasimod in Colitis, Ulcerative — 3 open to participants now, 5 under way, 2 of them phase 3. etrasimod · Colitis, Ulcerative.

Enrollment
8th of 12
118 · median 195
Started
2016
the only one that year
Phase 2
6 of 12
2 open now
Registered
2nd of 12
by date
Lead sponsor
4 of 12
Arena Pharmaceuticals

Among the 12 studies testing etrasimod in Colitis, Ulcerative, this one is the 8th largest by enrollment, is the only one that started in 2016, is one of 6 in phase 2, and was the 2nd registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

3 of the 12 studies testing etrasimod in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About etrasimod

etrasimod: first FDA approval 2023 (VELSIPITY), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing etrasimod in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether etrasimod (APD334) is a safe and effective treatment for ulcerative colitis after 52 weeks of treatment.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who completed the APD334-003 (NCT02447302) study

Exclusion criteria

Exclusion Criteria:

  • Participants who did not complete the APD334-003 study
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Enrollment
118 participants (actual)

Study arms

  • Experimental
    Etrasimod 2 mg

    Drug: Etrasimod

  • Active comparator
    Placebo

    Drug: Placebo

Interventions

  • Also known as: APD334

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs)

    A TEAE was defined as any adverse event (AE) that occurred after the first dose of study drug in the APD334-005 (NCT02536404) study, including any AE that started in Study APD334-003 (NCT02447302) and was ongoing, worsened, or ended in Study APD334-005. A SAE was any untoward medical occurrence that at any dose resulted in the following outcomes: death, was life-threatening, required/prolonged hospitalization, disability/incapacity, congenital anomaly/birth defect, and important medical events.

    Time frame: Up to Week 48 (up to 30 days following discontinuation of the study drug)

Secondary outcomes

  1. Proportion of Participants Who Achieved Clinical Response

    A participant was considered to have achieved clinical response if he/she met the criteria of clinical remission or met criteria of clinical response. Clinical remission was defined as individual subscores of the 3-component Mayo Clinic score as follows: (1) an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, (2) a rectal bleeding score of 0, and (3) a stool frequency score of 0 or 1 with a decrease of ≥ 1 point at Week 46 compared to APD334-003 baseline. Clinical response was defined as a decrease in 3-component Mayo Clinic score of ≥ 2 points and at least 30% with either a decrease of rectal bleeding of ≥ 1 or rectal bleeding score of 0 or 1 at Week 46 compared with baseline of study APD334-003. A score of 0 = normal and 1 = mild disease.

    Time frame: Week 46 (extension study APD334-005)

  2. Proportion of Participants Who Achieved Clinical Response at Week 12 in APD334-003 and Maintained Clinical Response at Week 46 in APD334-005

    A participant was considered to have achieved clinical response if he/she met the criteria of clinical remission or met criteria of clinical response. Clinical remission was defined as individual subscores of the 3-component Mayo Clinic score as follows: (1) an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, (2) a rectal bleeding score of 0, and (3) a stool frequency score of 0 or 1 with a decrease of ≥ 1 point at Week 46 compared to APD334-003 baseline. Clinical response was defined as a decrease in 3-component Mayo Clinic score of ≥ 2 points and at least 30% with either a decrease of rectal bleeding of ≥ 1 or rectal bleeding score of 0 or 1 at Week 46 compared with baseline of study APD334-003. A score of 0 = normal and 1 = mild disease.

    Time frame: Week 12 (core study APD334-003) and Week 46 (extension study APD334-005)

  3. Proportion of Participants Who Achieved Clinical Remission

    A participant was considered to have achieved clinical remission if he/she had: (1) an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, (2) a rectal bleeding score of 0, and (3) a stool frequency score of 0 or 1 with a decrease of ≥ 1 point at Week 46 compared with baseline of study APD334-003. A score of 0 = normal and 1 = mild disease.

    Time frame: Week 46 (extension study APD334-005)

  4. Proportion of Participants Who Achieved Clinical Remission at Week 12 in APD334-003 and Also Maintained Clinical Remission at Week 46 in APD334-005

    A participant was considered to have achieved clinical remission if he/she had: (1) an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, (2) a rectal bleeding score of 0, and (3) a stool frequency score of 0 or 1 with a decrease of ≥ 1 point at Week 46 compared with baseline of study APD334-003. A score of 0 = normal and 1 = mild disease.

    Time frame: Week 12 (core study APD334-003) and Week 46 (extension study APD334-005)

07

Results

Posted Nov 26, 2021

Participant flow

Participant flow — Overall Study
MilestoneEtrasimod 2 mgPlacebo
Started1126
Completed925
Not completed201
Withdrew: Adverse event50
Withdrew: Withdrawal by subject41
Withdrew: Physician decision100
Withdrew: Sponsor decision10

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs)

A TEAE was defined as any adverse event (AE) that occurred after the first dose of study drug in the APD334-005 (NCT02536404) study, including any AE that started in Study APD334-003 (NCT02447302) and was ongoing, worsened, or ended in Study APD334-005. A SAE was any untoward medical occurrence that at any dose resulted in the following outcomes: death, was life-threatening, required/prolonged hospitalization, disability/incapacity, congenital anomaly/birth defect, and important medical events.

Time frame:
Up to Week 48 (up to 30 days following discontinuation of the study drug)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs)
ParticipantsEtrasimod 2 mgPlacebo
TEAEs675
Treatment-emergent SAEs70
SecondaryProportion of Participants Who Achieved Clinical Response

A participant was considered to have achieved clinical response if he/she met the criteria of clinical remission or met criteria of clinical response. Clinical remission was defined as individual subscores of the 3-component Mayo Clinic score as follows: (1) an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, (2) a rectal bleeding score of 0, and (3) a stool frequency score of 0 or 1 with a decrease of ≥ 1 point at Week 46 compared to APD334-003 baseline. Clinical response was defined as a decrease in 3-component Mayo Clinic score of ≥ 2 points and at least 30% with either a decrease of rectal bleeding of ≥ 1 or rectal bleeding score of 0 or 1 at Week 46 compared with baseline of study APD334-003. A score of 0 = normal and 1 = mild disease.

Time frame:
Week 46 (extension study APD334-005)
Reported as:
Number · Percentage of participants
Proportion of Participants Who Achieved Clinical Response
Percentage of participantsEtrasimod 2 mgPlacebo
Proportion of Participants Who Achieved Clinical Response78.6 (69.9 to 85.7)75.0 (24.9 to 98.7)
SecondaryProportion of Participants Who Achieved Clinical Response at Week 12 in APD334-003 and Maintained Clinical Response at Week 46 in APD334-005

A participant was considered to have achieved clinical response if he/she met the criteria of clinical remission or met criteria of clinical response. Clinical remission was defined as individual subscores of the 3-component Mayo Clinic score as follows: (1) an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, (2) a rectal bleeding score of 0, and (3) a stool frequency score of 0 or 1 with a decrease of ≥ 1 point at Week 46 compared to APD334-003 baseline. Clinical response was defined as a decrease in 3-component Mayo Clinic score of ≥ 2 points and at least 30% with either a decrease of rectal bleeding of ≥ 1 or rectal bleeding score of 0 or 1 at Week 46 compared with baseline of study APD334-003. A score of 0 = normal and 1 = mild disease.

Time frame:
Week 12 (core study APD334-003) and Week 46 (extension study APD334-005)
Reported as:
Number · Percentage of participants
Proportion of Participants Who Achieved Clinical Response at Week 12 in APD334-003 and Maintained Clinical Response at Week 46 in APD334-005
Percentage of participantsEtrasimod 2 mgPlacebo
Proportion of Participants Who Achieved Clinical Response at Week 12 in APD334-003 and Maintained Clinical Response at Week 46 in APD334-00539.3 (30.3 to 48.8)50.0 (9.8 to 90.2)
SecondaryProportion of Participants Who Achieved Clinical Remission

A participant was considered to have achieved clinical remission if he/she had: (1) an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, (2) a rectal bleeding score of 0, and (3) a stool frequency score of 0 or 1 with a decrease of ≥ 1 point at Week 46 compared with baseline of study APD334-003. A score of 0 = normal and 1 = mild disease.

Time frame:
Week 46 (extension study APD334-005)
Reported as:
Number · Percentage of participants
Proportion of Participants Who Achieved Clinical Remission
Percentage of participantsEtrasimod 2 mgPlacebo
Proportion of Participants Who Achieved Clinical Remission39.3 (30.3 to 48.8)25.0 (1.3 to 75.1)
SecondaryProportion of Participants Who Achieved Clinical Remission at Week 12 in APD334-003 and Also Maintained Clinical Remission at Week 46 in APD334-005

A participant was considered to have achieved clinical remission if he/she had: (1) an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, (2) a rectal bleeding score of 0, and (3) a stool frequency score of 0 or 1 with a decrease of ≥ 1 point at Week 46 compared with baseline of study APD334-003. A score of 0 = normal and 1 = mild disease.

Time frame:
Week 12 (core study APD334-003) and Week 46 (extension study APD334-005)
Reported as:
Number · Percentage of participants
Proportion of Participants Who Achieved Clinical Remission at Week 12 in APD334-003 and Also Maintained Clinical Remission at Week 46 in APD334-005
Percentage of participantsEtrasimod 2 mgPlacebo
Proportion of Participants Who Achieved Clinical Remission at Week 12 in APD334-003 and Also Maintained Clinical Remission at Week 46 in APD334-00514.3 (8.5 to 22.1)0 (0.0 to 52.7)

Adverse events

Collected over Up to Week 48 (up to 30 days following discontinuation of the study drug). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Etrasimod 2 mg0/112 (0%)7/112 (6.3%)66/112 (58.9%)
Placebo0/6 (0%)0/6 (0%)5/6 (83.3%)
Most frequent serious events
Most frequent serious events
EventEtrasimod 2 mgPlacebo
Colitis ulcerativeGastrointestinal disorders3/1120/6
Iron deficiency anaemiaBlood and lymphatic system disorders2/1120/6
Atrial fibrillationCardiac disorders1/1120/6
Large intestine perforationGastrointestinal disorders1/1120/6
PancreatitisGastrointestinal disorders1/1120/6
Proctitis ulcerativeGastrointestinal disorders1/1120/6
GastroenteritisInfections and infestations1/1120/6
Fine motor skill dysfunctionNervous system disorders1/1120/6
Transient ischaemic attackNervous system disorders1/1120/6
Cystitis haemorrhagicRenal and urinary disorders1/1120/6
Most frequent other events
Showing 10 of 28
Most frequent other events
EventEtrasimod 2 mgPlacebo
Back painMusculoskeletal and connective tissue disorders4/1122/6
NasopharyngitisInfections and infestations6/1122/6
Faecal calprotectin increasedInvestigations3/1121/6
Carpal tunnel syndromeNervous system disorders1/1121/6
VitreousEye disorders0/1121/6
Colitis ulcerativeGastrointestinal disorders16/1121/6
NauseaGastrointestinal disorders5/1121/6
Dental cariesGastrointestinal disorders0/1121/6
GastritisGastrointestinal disorders0/1121/6
GlossodyniaGastrointestinal disorders0/1121/6

Baseline characteristics

Baseline data are reported for members of the Safety Population, comprised of all participants who received study medication in the extension study APD334-005 (NCT02536404).

Age, Continuous
Age, Continuous(Years)Etrasimod 2 mgPlaceboTotal
Mean43.7 ± 13.2550.2 ± 13.9344.0 ± 13.30
Sex: Female, Male
Sex: Female, Male(Participants)Etrasimod 2 mgPlaceboTotal
Female44347
Male68371
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Etrasimod 2 mgPlaceboTotal
Hispanic or Latino404
Not Hispanic or Latino1086114
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Etrasimod 2 mgPlaceboTotal
American Indian or Alaska Native000
Asian404
Native Hawaiian or Other Pacific Islander101
Black or African American101
White1046110
More than one race101
Unknown or Not Reported101
08

Study locations

127 sites
  • Arena 1119
    Birmingham, Alabama 35294, United States
  • Arena 1133
    Dothan, Alabama 36305, United States
  • Arena 1143
    Thousand Oaks, California 91360, United States
  • Arena 1107
    Hollywood, Florida 33021, United States
  • Arena 1138
    Miami, Florida 33134, United States
  • Arena 1123
    Naples, Florida 34102, United States
  • Arena 1141
    Orlando, Florida 32825, United States
  • Arena 1106
    Port Orange, Florida 32127, United States
  • Arena 1137
    Sweetwater, Florida 33172, United States
  • Arena 1131
    Chicago, Illinois 60611, United States
  • Arena 1139
    Hoffman Estates, Illinois 60169, United States
  • Arena 1127
    Urbana, Illinois 61801, United States
  • Arena 1113
    Chevy Chase, Maryland 20815, United States
  • Arena 1142
    Traverse City, Michigan 49686, United States
  • Arena 1111
    Troy, Michigan 48098, United States
  • Arena 1109
    Great Neck, New York 11021, United States
  • Arena 1114
    Rochester, New York 14642, United States
  • Arena 1118
    Raleigh, North Carolina 27612, United States
  • Arena 1112
    Cincinnati, Ohio 45267, United States
  • Arena 1117
    Pittsburgh, Pennsylvania 15219, United States
  • Arena 1105
    Germantown, Tennessee 38138, United States
  • Arena 1102
    Hermitage, Tennessee 37076, United States
  • Arena 1136
    DeSoto, Texas 75115, United States
  • Arena 1121
    Houston, Texas 77030, United States
  • Arena 1116
    Temple, Texas 76508, United States
  • Arena 1103
    Ogden, Utah 84405, United States
  • Arena 1130
    Richmond, Virginia 23298, United States
  • Arena 1128
    Roanoke, Virginia 24014, United States
  • Arena 1115
    Seattle, Washington 98101, United States
  • Arena 1101
    Seattle, Washington 98195, United States
  • Arena 1108
    Wauwatosa, Wisconsin 53226, United States
  • Arena 1604
    Kingswood, 2747, Australia
  • Arena 1605
    Randwick, 2031, Australia
  • Arena 1607
    Subiaco, 6008, Australia
  • Arena 1490
    Wien, 1090, Austria
  • Arena 1472
    Edegem, 2650, Belgium
  • Arena 1464
    Kortrijk, 8500, Belgium
  • Arena 1473
    Leuven, 3000, Belgium
  • Arena 1421
    Ruse, 1407, Bulgaria
  • Arena 1417
    Sofia, 1407, Bulgaria
  • Arena 1410
    Sofia, 1527, Bulgaria
  • Arena 1409
    Sofia, 1784, Bulgaria
  • Arena 1407
    Sofia, 1797, Bulgaria
  • Arena 1425
    Varna, 9010, Bulgaria
  • Arena 1202
    Winnipeg, Manitoba R3A 1R9, Canada
  • Arena 1210
    Bridgewater, Nova Scotia B4V 3N2, Canada
  • Arena 1206
    London, Ontario N6A 4G5, Canada
  • Arena 1208
    Sudbury, Ontario P3E 1H5, Canada
  • Arena 1209
    Sudbury, Ontario P3E 6C3, Canada
  • Arena 1204
    Toronto, Ontario M5G 1X5, Canada
  • Arena 1455
    Praha 4, 140 59, Czechia
  • Arena 1443
    Amiens Cedex 1, 80054, France
  • Arena 1418
    Clichy, 92110, France
  • Arena 1437
    Lille Cedex 1443, 59037, France
  • Arena 1476
    Paris, 75010, France
  • Arena 1480
    Pierre-Benite, 693110, France
  • Arena 1423
    Saint-Etienne Cedex 1, 42055, France
  • Arena 1457
    Vandoeuvre-les-Nancy, 54511, France
  • Arena 1479
    Hamburg, 20249, Germany
  • Arena 1422
    Hamburg, 22559, Germany
  • Arena 1470
    Hanover, 30625, Germany
  • Arena 1446
    Kiel, 24105, Germany
  • Arena 1489
    Leipzig, 04103, Germany
  • Arena 1497
    Oldenburg, 26123, Germany
  • Arena 1444
    Ulm, 89073, Germany
  • Arena 1478
    Bekescsaba, 5600, Hungary
  • Arena 1431
    Budapest, 1036, Hungary
  • Arena 1471
    Budapest, 1062, Hungary
  • Arena 1492
    Budapest, 1062, Hungary
  • Arena 1505
    Debrecen, 4025, Hungary
  • Arena 1474
    Debrecen, 4032, Hungary
  • Arena 1477
    Szombathely, 9700, Hungary
  • Arena 1705
    Beer Sheva, 84101, Israel
  • Arena 1702
    Haifa, 31096, Israel
  • Arena 1706
    Holon, 58100, Israel
  • Arena 1704
    Jerusalem, 91031, Israel
  • Arena 1703
    Petah-Tikva, 49100, Israel
  • Arena 1615
    Wonju, Gangwon-do 26426, Korea, Republic of
  • Arena 1614
    Daegu, 42415, Korea, Republic of
  • Arena 1610
    Incheon, 21565, Korea, Republic of
  • Arena 1462
    Riga, 1002, Latvia
  • Arena 1475
    Riga, 1006, Latvia
  • Arena 1484
    Vilnius, 8661, Lithuania
  • Arena 1601
    Christchurch, 8011, New Zealand
  • Arena 1439
    Bydgoszcz, 85-681, Poland
  • Arena 1486
    Elblag, 82-300, Poland
  • Arena 1495
    Kielce, 25-364, Poland
  • Arena 1451
    Krakow, 31-009, Poland
  • Arena 1438
    Lodz, 90-302, Poland
  • Arena 1458
    Poznań, 60-856, Poland
  • Arena 1428
    Rzeszow, 35-068, Poland
  • Arena 1456
    Sopot, 81-756, Poland
  • Arena 1494
    Wroclaw, 54-144, Poland
  • Arena 1491
    Bucharest, 010719, Romania
  • Arena 1406
    Bucharest, 020125, Romania
  • Arena 1441
    Bucharest, 050098, Romania
  • Arena 1436
    Iasi, 700506, Romania
  • Arena 1420
    Oradea, 410159, Romania
  • Arena 1405
    Timisoara, 300002, Romania
  • Arena 1493
    Timisoara, 300736, Romania

Showing the first 100 of 127 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Nov 2018, 33 months.

Results were first posted in Nov 2021, 3 years after primary completion. A results delay was requested in Oct 2019.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 33 months is above that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2015
First posted
Aug 31, 2015
StartActual
Jan 25, 2016
Primary completionActual
Nov 1, 2018
CompletionActual
Nov 1, 2018
Results delay requested
Oct 31, 2019
Results first posted
Nov 26, 2021
Last update
Nov 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02536404
Responsible party
Sponsor
First posted
Aug 31, 2015
Start date
Jan 25, 2016
Primary completion
Nov 1, 2018
Completion
Nov 1, 2018
Results posted
Nov 26, 2021
Last update
Nov 26, 2021

Study contacts

Arena CT.gov Administrator
study director · Arena Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etrasimod

Start the discussion